Patient-reported outcomes item selection for bladder cancer patients in chemo- or immunotherapy

Gry Assam Taarnhøj, Henriette Lindberg, Christoffer Johansen, Helle Pappot, Gry Assam Taarnhøj, Henriette Lindberg, Christoffer Johansen, Helle Pappot

Abstract

Background: Selection of specific patient-reported outcomes (PROs) for cancer patients requires careful consideration to the purpose and population at aim. Here we report the process of choosing which items to include in a bladder cancer population in chemo- or immunotherapy based on the Patient-Reported Outcomes Version of the Common Terminology Criteria of Adverse Events (PRO-CTCAE).

Methods: Initial PRO-CTCAE symptoms were chosen through 1) medical record audit 2) patient interviews 3) summary of product characteristics from European Medicines Agency and Food and Drug Administration for the applied chemotherapies, and 4) toxicity reporting from Phase 2 and 3 trials for immunotherapies applied in patients with urothelial cancer. The selected questions were applied in a prospective cohort of 78 bladder cancer patients receiving chemo- or immunotherapy at Rigshospitalet and Herlev Hospital, Denmark. Symptoms tested in this population were selected for the final module if they appeared in ≥3 of the following groupings a) the most prevalent PRO-CTCAE symptoms grade ≥ 2 overall during treatment b) the PRO-CTCAE symptoms reported in conjunction with hospital admissions or mentioned in focus group interviews discussing which symptoms were prevalent in this patient group with specialized c) nurses or d) physicians. The authors also included symptoms in the final module if they were present in two of the above groups and defined as actionable by clinicians.

Results: From the initial selection of PRO-CTCAE symptoms, a total of 45 PRO-CTCAE symptoms explored by 84 PRO-CTCAE questions were retrieved. Through the second selection process based on the described criteria, the study group agreed on 15 PRO-CTCAE symptoms explored by 30 PRO-CTCAE items to be appropriate and relevant for the bladder population during medical oncological treatment.

Conclusions: The selection of disease specific PROs in a bladder cancer population was feasible. The process revealed several steps of selection needed in order to reach a final module for clinical application.

Keywords: Bladder cancer; Chemotherapy; Immunotherapy; Item selection; Patient-reported outcomes.

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Item Selection Process. legend: *Rosenberg et al., Lancet 2016, Bellmunt et al., NEJM, 2017

References

    1. Trotti A, Colevas AD, Setser A, Basch E. Patient-reported outcomes and the evolution of adverse event reporting in oncology. Journal of Clinical Oncology. 2007;25(32):5121–5127. doi: 10.1200/JCO.2007.12.4784.
    1. Di MM, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, et al. Symptomatic toxicities experienced during anticancer treatment: Agreement between patient and physician reporting in three randomized trials. Journal of Clinical Oncology. 2015;33(8):910–915. doi: 10.1200/JCO.2014.57.9334.
    1. Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, et al. Patient versus clinician symptom reporting using the National Cancer Institute common terminology criteria for adverse events: Results of a questionnaire-based study. The Lancet Oncology. 2006;7(11):903–909. doi: 10.1016/S1470-2045(06)70910-X.
    1. Basch, E., Reeve, B. B., Mitchell, S. A., Clauser, S. B., Minasian, L. M., Dueck, A. C., et al. (2014). Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Journal of the National Cancer Institute, 106(9).
    1. Basch, E., Deal, A. M., Dueck, A. C., Scher, H. I., Kris, M. G., Hudis, C., et al. (2017). Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA.
    1. Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial. Journal of Clinical Oncology. 2016;34(6):557–565. doi: 10.1200/JCO.2015.63.0830.
    1. Berry DL, Hong F, Halpenny B, Partridge AH, Fann JR, Wolpin S, et al. Electronic self-report assessment for cancer and self-care support: Results of a multicenter randomized trial. Journal of Clinical Oncology. 2014;32(3):199–205. doi: 10.1200/JCO.2013.48.6662.
    1. Denis, F., Yossi, S., Septans, A. L., Charron, A., Voog, E., Dupuis, O., et al. (2017). Improving survival in patients treated for a lung cancer using self-evaluated symptoms reported through a web application. American Journal of Clinical Oncology.
    1. Denis, F., Lethrosne, C., Pourel, N., Molinier, O., Pointreau, Y., Domont, J., et al. (2017). Randomized trial comparing a web-mediated follow-up with routine surveillance in lung cancer patients. Journal of the National Cancer Institute, 109(9).
    1. US Food and Drug Administration: Guidance for Industry on Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims; Availability 2009. [Available from: ]. Accessed 1 Feb 2019.
    1. Nissen, A., Bager, L., & Pappot, H. (2019). The use of PRO in adverse event identification during cancer therapy - choosing the right questions to ask. Acta oncologica (Stockholm, Sweden), 1–7.
    1. Guancial EA, Roussel B, Bergsma DP, Bylund KC, Sahasrabudhe D, Messing E, et al. Bladder cancer in the elderly patient: Challenges and solutions. Clinical Interventions in Aging. 2015;10:939–949.
    1. Scosyrev E, Wu G, Golijanin D, Messing E. Non-bladder cancer mortality in patients with urothelial cancer of the bladder. Urologic Oncology. 2013;31(5):656–663. doi: 10.1016/j.urolonc.2011.03.005.
    1. Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, et al. A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. European Urology. 2012;62(3):523–533. doi: 10.1016/j.eururo.2012.05.048.
    1. Niegisch G, Lorch A, Droller MJ, Lavery HJ, Stensland KD, Albers P. Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: Which patients benefit? European Urology. 2013;64(3):355–357. doi: 10.1016/j.eururo.2013.06.002.
    1. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet. 2009;374(9685):239–249. doi: 10.1016/S0140-6736(09)60491-8.
    1. Taarnhoej GA, Lindberg H, Johansen C, Pappot H. Patient-reported outcomes and quality of life in bladder cancer patients receiving chemotherapy; a real-life experience. Under review in Scientific Reports. 2019.
    1. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–1920. doi: 10.1016/S0140-6736(16)00561-4.
    1. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. The New England Journal of Medicine. 2017;376(11):1015-26.PMC5635424. doi: 10.1056/NEJMoa1613683.
    1. Trask PC, Dueck AC, Piault E, Campbell A. Patient-reported outcomes version of the common terminology criteria for adverse events: Methods for item selection in industry-sponsored oncology clinical trials. Clinical Trials (London, England) 2018;15(6):616–623. doi: 10.1177/1740774518799985.
    1. Schmidt H, Merkel D, Koehler M, Flechtner HH, Sigle J, Klinge B, et al. PRO-ONKO-selection of patient-reported outcome assessments for the clinical use in cancer patients-a mixed-method multicenter cross-sectional exploratory study. Support Care Cancer. 2016;24(6):2503–2512. doi: 10.1007/s00520-015-3055-4.
    1. Nordan L, Blanchfield L, Niazi S, Sattar J, Coakes CE, Uitti R, et al. Implementing electronic patient-reported outcomes measurements: Challenges and success factors. BMJ Quality and Safety. 2018;27(10):852–856. doi: 10.1136/bmjqs-2018-008426.
    1. Taarnhoj GA, Johansen C, Pappot H. Quality of life in bladder cancer patients receiving medical oncological treatment; a systematic review of the literature. Health and Quality of Life Outcomes. 2019;17(1):20. doi: 10.1186/s12955-018-1077-6.
    1. Hasson F, Keeney S, McKenna H. Research guidelines for the Delphi survey technique. Journal of Advanced Nursing. 2000;32(4):1008–1015.
    1. Christensen AI, Ekholm O, Gray L, Glümer C, Juel K. What is wrong with non-respondents? Alcohol-, drug- and smoking-related mortality and morbidity in a 12-year follow-up study of respondents and non-respondents in the Danish health and morbidity survey. Addiction. 2015;110(9):1505–1512. doi: 10.1111/add.12939.
    1. Tolonen H, Laatikainen T, Helakorpi S, Talala K, Martelin T, Prattala R. Marital status, educational level and household income explain part of the excess mortality of survey non-respondents. European Journal of Epidemiology. 2010;25(2):69–76. doi: 10.1007/s10654-009-9389-9.
    1. Une H, Miyazaki M, Momose Y. Comparison of mortality between respondents and non-respondents in a mail survey. Journal of Epidemiology. 2000;10(3):136–139. doi: 10.2188/jea.10.136.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel